The prevalence and incidence of atrial fibrillation (AF) are increasing rapidly. Key recommendations in management of AF include prompt anticoagulation in patients with elevated risk of thromboembolic complications (CHA2DS2VASc score ≥ 2), proper use of antiarrhythmic drugs and invasive therapies in symptomatic patients and adequate rate control in patients with permanent AF. The selection between the direct oral anticoagulants (DOAC) and warfarin is based on careful evaluation of the benefits and disadvantages of the drugs. DOAC is usually a good choice except for the patients with mitral valve stenosis or prosthetic heart valve.
Pekka Raatikainen (Chair)